Back to Search
Start Over
Weight gain and metabolic disturbances in people living with HIV who start antiretroviral therapy with, or switch to, bictegravir/emtricitabine/tenofovir alafenamide after 48 weeks of treatment: A real-world prospective study.
- Source :
- International Journal of STD & AIDS; Jan2024, Vol. 35 Issue 1, p33-38, 6p
- Publication Year :
- 2024
Details
- Language :
- English
- ISSN :
- 09564624
- Volume :
- 35
- Issue :
- 1
- Database :
- Complementary Index
- Journal :
- International Journal of STD & AIDS
- Publication Type :
- Academic Journal
- Accession number :
- 174837723
- Full Text :
- https://doi.org/10.1177/09564624231196605